Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Скринер
Новости
О нас

GSK - GSK plc Последние новости | Finranks

Home

/

GSK

G

GSK plc (GSK)

NYQ – Цена в реальном времени. Валюта: USD

50.90

+1.09 (2.19%)

При закрытии: May 12, 2026, 4:00 PM EDT

51.00

+0.10 (0.20%)

После закрытия: May 12, 2026, 7:59 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

GSK to team up with Sino Biopharma for China launch of hepatitis B treatment

GSK to team up with Sino Biopharma for China launch of hepatitis B treatment

GSK on Monday ‌said it had entered into ⁠a strategic collaboration with Hong Kong-listed Sino Biopharmaceutical to ‌accelerate ⁠the launch of its hepatitis ⁠B treatment bepirovirsen in ⁠mainland ⁠China.

Julie Bowen and Ty Burrell team up with GSK to raise awareness about meningitis risks for teens and young adults

Julie Bowen and Ty Burrell team up with GSK to raise awareness about meningitis risks for teens and young adults

PHILADELPHIA--(BUSINESS WIRE)-- #Adolescents--Julie Bowen and Ty Burrell team up with GSK to raise awareness about meningitis risks for teens and young adults.

The Most Important Part of These 3 Big Pharma Earnings Reports Wasn't the Beat

The Most Important Part of These 3 Big Pharma Earnings Reports Wasn't the Beat

Earnings season is in full swing, and on April 29, three Big Pharma mainstays reported Q1 2026 earnings. Investors were looking for strong results—and strong guidance—that could serve as a sorely needed tailwind for the healthcare sector.

Why GSK (GSK) is a Top Value Stock for the Long-Term

Why GSK (GSK) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

JP Morgan retains 'underweight' on GSK with £17 price target as earnings upgrade potential seen as limited

JP Morgan retains 'underweight' on GSK with £17 price target as earnings upgrade potential seen as limited

Bank sits 5-10% below consensus on core earnings from 2027, citing need for pipeline success and new launch execution JP Morgan has retained its underweight rating on GSK PLC (LSE:GSK, NYSE:GSK) with a June 2027 price target of £17, arguing that near-term earnings upgrade potential is limited and that the pharmaceutical group's longer-term outlook remains contingent on pipeline success and the execution of new product launches. Analyst Zain Ebrahim made modest forecast changes following GSK's first-quarter 2026 results, including foreign exchange-related adjustments of 0% to 1% to sales forecasts across 2026 to 2031 and upgrades of 1% to 2% to core operating profit estimates.

GSK plc (GSK) Q1 2026 Earnings Call Transcript

GSK plc (GSK) Q1 2026 Earnings Call Transcript

GSK plc (GSK) Q1 2026 Earnings Call Transcript

GSK Q1 Earnings Beat Estimates, Specialty Medicines Drive Sales Growth

GSK Q1 Earnings Beat Estimates, Specialty Medicines Drive Sales Growth

GSK Q1 earnings and revenues beat estimates as Specialty Medicines lifted sales, with HIV, oncology and respiratory growth. The guidance for 2026 remains unchanged.

Видео

3 International Stocks to Buy for 2026

BREAKING: Trump strikes major deal with UK on drug pricing

Пресс-релизы

Julie Bowen and Ty Burrell team up with GSK to raise awareness about meningitis risks for teens and young adults

Julie Bowen and Ty Burrell team up with GSK to raise awareness about meningitis risks for teens and young adults

PHILADELPHIA--(BUSINESS WIRE)-- #Adolescents--Julie Bowen and Ty Burrell team up with GSK to raise awareness about meningitis risks for teens and young adults.

04.11.2025

Neutral

3 Dividend Stocks for November 2025

Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days

Samsung Biologics completes acquisition of GSK's manufacturing facility in Rockville, Maryland

Samsung Biologics completes acquisition of GSK's manufacturing facility in Rockville, Maryland

Adds 60,000 liters of drug substance capacity, bringing the total to 845,000 liters Marks Samsung Biologics' geographical diversification and establishes its first U.S. manufacturing presence, expanding regional client support Plans further investments to add capabilities and strengthen long-term operations at the Rockville site INCHEON, South Korea and ROCKVILLE, MD., March 31, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced the completion of its acquisition of a manufacturing facility in Rockville, Maryland from GSK, establishing the company's first manufacturing presence in the United States.

GSK's RSV Vaccine, AREXVY, Approved in US for Expanded Age Indication in Adults Aged 18–49 Years at Increased Risk

GSK's RSV Vaccine, AREXVY, Approved in US for Expanded Age Indication in Adults Aged 18–49 Years at Increased Risk

PHILADELPHIA--(BUSINESS WIRE)--GSK's RSV vaccine, AREXVY, approved in US for expanded age indication in adults aged 18–49 years at increased risk.

35Pharma to be Acquired by GSK to Accelerate Development of HS235, a Potential Best-in-Class Investigational Medicine for Pulmonary Hypertension (PH)

35Pharma to be Acquired by GSK to Accelerate Development of HS235, a Potential Best-in-Class Investigational Medicine for Pulmonary Hypertension (PH)

MONTREAL, Feb. 25, 2026 (GLOBE NEWSWIRE) -- 35Pharma, a Canada-based, private, clinical-stage biopharmaceutical company specialised in the development of novel protein-based therapeutics today announced it has entered into an agreement with GSK plc (GSK), under which GSK will acquire all of the outstanding equity interests in 35Pharma. The acquisition includes HS235, a potential best-in-class investigational medicine that has completed phase I healthy volunteer clinical trials with studies to start imminently in pulmonary arterial hypertension (PAH) and pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF).